La Jolla Pharmaceutical Company was granted Breakthrough Therapy designation by the FDA for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria.
Japanese-based Takeda Pharmaceutical Company and Medicines for Malaria Venture in Switzerland (MMV) have signed an agreement to start a new joint research programme aimed at finding lead compounds for malaria treatment.